Alan Lau

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers

Peter C.C. Fong, David S. Boss, Timothy A. Yap et al. · New England Journal of Medicine · 2009 · 3.6K citations · Full text

Medicine, Oncology, Pharmacology +17

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

Sven Rottenberg, Janneke E. Jaspers, Ariena Kersbergen et al. · Proceedings of the National Academy of Sciences · 2008 · 949 citations · Full text

Medicine, Oncology, Pharmacology +16

4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2<i>H</i>-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1

Keith Menear, Claire Adcock, Robert Boulter et al. · Journal of Medicinal Chemistry · 2008 · 586 citations · Full text

Medicine, Oncology, Pharmacology +16

Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i> -Mutated Mouse Mammary Tumors

Janneke E. Jaspers, Ariena Kersbergen, Ute Boon et al. · Cancer Discovery · 2012 · 515 citations · Full text

Medicine, Oncology, Pharmacology +17

Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin

Bastiaan Evers, Rinske Drost, Eva Schut et al. · Clinical Cancer Research · 2008 · 334 citations · Full text

Medicine, Oncology, Pharmacology +16